Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26739725 | 0.82 | MEN1 (0.48) | POLBSYKNPC1MEN1KMT2A | |
| SCHEMBL26739715 | 0.82 | EPHX2 (0.51) | NPC1ALDH1A1KDM4ELTA4H | |
| SCHEMBL14621966 | 0.81 | EPHX2 (0.59) | NPC1ALDH1A1KDM4E | |
| SCHEMBL12943762 | 0.81 | POLB (0.57) | POLBSYKNPC1MEN1KMT2A | |
| SCHEMBL27289103 | 0.81 | POLB (0.57) | POLBSYKNPC1MEN1KMT2A | |
| SCHEMBL113405 | 0.80 | LTA4H (0.63) | NPC1ALDH1A1KDM4ELTA4HRAB9A | |
| SCHEMBL10104432 | 0.80 | POLB (0.53) | POLBSYKNPC1MEN1KMT2A | |
| SCHEMBL13534008 | 0.80 | POLB (0.56) | POLBSYKNPC1MEN1KMT2A | |
| SCHEMBL16533945 | 0.77 | SYK (0.53) | POLBSYKNPC1ALDH1A1KDM4E | |
| SCHEMBL16533933 | 0.76 | KDM4E (0.57) | POLBSYKNPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | POLB 3996/4885SYK 3787/4885NPC1 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.